Drugs / E2086
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials · 1 met primary | ||||||
| Phase 1 | NCT07308236 | Dec 2025 → Feb 2026 overdue | — | Eisai Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06481488 | Jun → Dec 2024 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06462404 | Jun 2024 → Mar 2025 | narcolepsy 1 | Eisai Inc. | Completed | Met primary |
| Phase 1 | NCT05745207 | Feb 2023 → Jan 2024 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07493265 | Mar 2026 → Feb 2027 expected | narcolepsy | Eisai Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-02-16 | Eisai Inc. | Regulatory Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy eisai.com ↗
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has received an orphan drug designation for its in-house discovered and developed novel selective orexin 2 receptor agonist E2086, with prospective indication for narcolepsy, from the Ministry of Health, Labour and Welfare (MHLW). |
| 2025-09-08 | Eisai Inc. | Results Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025 E2086 Showed Potential to Improve Wakefulness in People Living with Narcolepsy Type 1 eisai.com ↗
These data demonstrate that once-daily dosing of E2086 has the potential to improve daytime wakefulness in individuals with narcolepsy type 1 (NT1). |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E2086 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06462404 ↗ |
| Route | Oral | “tablets, orally, once on Day 1.” NCT05745207 ↗ |